Wayshine Biopharm International

Wayshine Biopharm is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics for immune-mediated inflammatory diseases and oncology. The company's lead candidate, WSB-1001, is a highly selective Tyrosine kinase 2 (TYK2) inhibitor currently in Phase 2 clinical development for the treatment of moderate-to-severe plaque psoriasis. Wayshine utilizes its internal drug discovery engine to design molecules with superior selectivity and safety profiles, aiming to overcome the limitations of first-generation kinase inhibitors. Headquartered in Guangzhou, China, the company focuses on addressing significant unmet medical needs in global markets through a pipeline of targeted therapies. Its research and development efforts are supported by a team of industry veterans with extensive experience in medicinal chemistry and clinical development.